The Pharmaceuticals and Medical Devices Agency panel has determined that the human (allogeneic) iPS cell-derived cardiomyocyte sheet IPSOC-1 can be approved with conditions and time limitations, and formal approval by the Ministry of Health, Labour and Welfare is expected.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4894","jir_company_name":"QUOLIPS, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4894-20260219-01.pdf","jir_short_summary":"The Pharmaceuticals and Medical Devices Agency panel has determined that the human (allogeneic) iPS cell-derived cardiomyocyte sheet IPSOC-1 can be approved with conditions and time limitations, and formal approval by the Ministry of Health, Labour and Welfare is expected.","jir_summary":"### Status of Manufacturing and Marketing Approval Review\nQUOLIPS, Inc. received a determination from the Pharmaceuticals and Medical Devices Agency Regenerative Medicine Products and Biologics Technology Subcommittee on 2026-02-19 that the human (allogeneic) iPS cell-derived cardiomyocyte sheet (IPSOC-1), applied for approval in April 2025, can be approved with attached conditions and a time limit. This product is intended to treat severe heart failure caused by ischemic cardiomyopathy, targeting patients for whom standard treatments are insufficient.\n\n### Future Outlook and Impact\nBased on this panel decision, formal manufacturing and marketing approval with conditions and a time limit is expected from the Ministry of Health, Labour and Welfare. While the impact on the consolidated financial results for this fiscal year is considered minimal, any significant developments will be disclosed promptly. IPSOC-1 was designated as a regenerative medicine product for rare diseases on 2025-10-24.","jir_financial_highlights":"Approval Status for Manufacturing and Marketing: Possible approval with conditions and time limitations (Unknown)\nTarget Product: Human (Allogeneic) iPS Cell-Derived Cardiomyocyte Sheet (IPSOC-1) (Unknown)\nExpected Approval Date: Unknown (Formal approval by the Ministry of Health, Labour and Welfare expected following the Pharmaceuticals and Medical Devices Agency panel decision on 2026-02-19) (Unknown)","jir_category":"","jir_hashtags":"#QUOLIPSInc, #ManufacturingAndMarketingApproval, #RegenerativeMedicine, #iPSCells, #NewProduct","jir_key_figures":"Date of Manufacturing and Marketing Approval Review Decision: 2026-02-19\nProduct Name: Human (Allogeneic) iPS Cell-Derived Cardiomyocyte Sheet (IPSOC-1)\nDesignation Date as Regenerative Medicine Product for Rare Diseases: 2025-10-24","jir_meta_title":"QUOLIPS, Inc. Obtains Conditional Approval Decision for iPS Cell-Derived Cardiomyocyte Sheet IPSOC-1","jir_meta_description":"QUOLIPS, Inc. received a conditional and time-limited approval decision from the Pharmaceuticals and Medical Devices Agency for the human (allogeneic) iPS cell-derived cardiomyocyte sheet IPSOC-1, with formal approval expected from the Ministry of Health, Labour and Welfare.","jir_og_title":"QUOLIPS Announces Status of Approval Review for iPS Cell-Derived Cardiomyocyte Sheet","jir_og_description":"QUOLIPS, Inc. obtained a decision of conditional approval possibility for manufacturing and marketing approval of IPSOC-1. High expectations remain for formal approval going forward.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17194,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-30275","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n